MedTrace Logo

Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome

NCT06782243 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2026-01-08

No results posted yet for this study

Summary

This study evaluates the effectiveness of high- and moderate-intensity statins in achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with acute coronary syndrome (ACS). The study aims to determine whether moderate-intensity statins can provide comparable benefits to high-intensity statins, particularly for patients at higher risk of adverse effects from higher doses. The findings may inform treatment decisions and reduce financial and clinical burdens on patients.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Moderate-Intensity Statins

Participants will be administered statins based on moderate intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 20 mg and rosuvastatin 10 mg.

DRUG

High-Intensity Statins

Participants will be administered statins based on high intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 40 mg and rosuvastatin 20 mg.

Sponsors & Collaborators

  • Khyber Teaching Hospital

    collaborator OTHER

  • Khyber Medical University Peshawar

    lead OTHER

Principal Investigators

  • Dr Shafeeq Mehmood, MBBS · Khyber Teaching Hospital

  • Muhammad Faheem Mehmood, MBBS · Khyber Teaching Hospital

  • Syed Muhammad Shabbir Ali Naqvi · Clinical Trial Unit, Khyber Medical University Peshawar

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-20
Primary Completion
2025-07-30
Completion
2025-08-25

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06782243 on ClinicalTrials.gov